Scarica l'app Stockscreener
0.2797
3.85%
0.0097
Precedente Chiudi:
$0.27
Aprire:
$0.27
Volume 24 ore:
805.26K
Relative Volume:
0.19
Capitalizzazione di mercato:
$7.83M
Reddito:
-
Utile/perdita netta:
$-22.71M
Rapporto P/E:
-0.0239
EPS:
-11.71
Flusso di cassa netto:
$-18.24M
1 W Prestazione:
-0.53%
1M Prestazione:
+16.83%
6M Prestazione:
-74.51%
1 anno Prestazione:
-88.51%
Intervallo 1D:
$0.2686
$0.30
Intervallo di 1 settimana:
$0.215
$0.30
Portata 52W:
$0.215
$4.0899
Genprex Inc Stock (GNPX) Company Profile
Nome
Genprex Inc
Settore
Industria
Telefono
512-537-7997
Indirizzo
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Confronta GNPX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
0.2816 | 6.67M | 0 | -22.71M | -18.24M | -11.71 |
|
ONC
Beigene Ltd Adr
|
236.72 | 25.21B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.61 | 110.94B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2632 | 40.72M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
607.21 | 62.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.73 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-01-26 | Iniziato | National Securities | Buy |
| 2019-04-29 | Iniziato | Noble Capital Markets | Outperform |
Genprex Inc Borsa (GNPX) Ultime notizie
WestPark Capital Leads Placement for GNPX | GNPX Stock News - GuruFocus
Genprex (GNPX) to Release Quarterly Earnings on Wednesday - Defense World
Things To Consider Before Buying Genprex Inc (NASDAQ: GNPX) - Stocksregister
Genprex and University of Pittsburgh sign new agreement to study GPX-002 for diabetes - BioWorld MedTech
Attention Investors: What’s Really Going On With Genprex Inc (NASDAQ: GNPX) - Stocksregister
Genprex Announces Research Agreement for Diabetes Therapy - TipRanks
Genprex (GNPX) Advances Diabetes Therapy Research with New Agreement | GNPX Stock News - GuruFocus
Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes | GNPX Stock News - GuruFocus
Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes - Nasdaq
Genprex (GNPX) Secures Exclusive Patent License for Gene Therapy - GuruFocus
Genprex (GNPX) Secures Exclusive Patent License for Gene Therapy | GNPX Stock News - GuruFocus
Genprex Secures Exclusive Patent License for Reqorsa - TipRanks
Genprex Signs Exclusive License to Additional Gene Therapy Techn - GuruFocus
Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma | GNPX Stock News - GuruFocus
Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma - PR Newswire
Geode Capital Management LLC Grows Position in Genprex, Inc. (NASDAQ:GNPX) - Defense World
Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions - ADVFN
Genprex Inc (NASDAQ: GNPX) Is The Number One Stock Currently Moving. - Stocksregister
Genprex (GNPX) Showcases Promising Results for Reqorsa Gene Ther - GuruFocus
Genprex Collaborators Report Positive Preclinical Data On The Use Of Reqorsa Gene Therapy - TradingView
Genprex Collaborators Report Positive Preclinical Data on the Us - GuruFocus
Financial Metrics Check: Genprex Inc (GNPX)’s Ratios for Trailing Twelve Months - DWinneX
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting - PR Newswire
Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting - The Malaysian Reserve
Genprex Collaborators to Present Positive Preclinical Data on Di - GuruFocus
Taking the lead: Genprex Inc (GNPX) - Sete News
Understanding the Risks of Investing in Genprex Inc (GNPX) - knoxdaily.com
Genprex collaborators report positive preclinical data on the use of Reqorsa gene therapy at the 2025 AACR Annual Meeting - Select Science
Genprex (GNPX) Secures Exclusive Patent License for Mesothelioma - GuruFocus
Indo-Asian News Service - Indo-Asian News Service (IANS)
Genprex secures exclusive license for mesothelioma gene therapy By Investing.com - Investing.com South Africa
Genprex secures exclusive license for mesothelioma gene therapy - Investing.com Australia
Choosing between riding the trend or protecting profits: Genprex Inc (GNPX) - uspostnews.com
Genprex Inc (NASDAQ: GNPX) Stock’s Potential for Success in the Coming Months - Marketing Sentinel
Genprex Signs Exclusive Technology License Agreement with New Yo - GuruFocus
Genprex (GNPX) Secures Exclusive License for Gene Therapy Patent - GuruFocus
Genprex Signs Agreement With New York University Langone Health - marketscreener.com
Revolutionary Gene Therapy Shows 84% Target Success in Mesothelioma Treatment: Genprex-NYU Partnership - Stock Titan
Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma - The Malaysian Reserve
Short Interest in Genprex, Inc. (NASDAQ:GNPX) Grows By 487.6% - Defense World
Stock Market Recap: Genprex Inc (GNPX) Concludes at 0.27, a 0.57 Surge/Decline - DWinneX
GNPX’s Stock Market Puzzle: Piecing Together 2023’s Performance - investchronicle.com
Now Is The Time To Build A Position In Genprex Inc (NASDAQ:GNPX) - Marketing Sentinel
Genprex Selected to Present Trial Design of Acclaim-3 Clinical T - GuruFocus
Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting - Seeking Alpha
Genprex Inc (GNPX) receives a Buy rating from National Securities - knoxdaily.com
Genprex presents promising gene therapy data for lung cancer By Investing.com - Investing.com South Africa
How Are Things Looking For Genprex Inc (NASDAQ: GNPX) For The Short Term? - Stocksregister
Genprex presents promising gene therapy data for lung cancer - Investing.com
Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings - GuruFocus
There is no doubt that Genprex Inc (GNPX) ticks all the boxes. - Sete News
Genprex Inc Azioni (GNPX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.24%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):